Loopbaan van Richard Chesworth
Eerdere bekende functies van Richard Chesworth
| Bedrijven | Functie | Begin | Einde |
|---|---|---|---|
| KYMERA THERAPEUTICS, INC. | Hoofd Techniek/Wetenschap/O&O | 27-08-2020 | 22-10-2021 |
| EPIZYME, INC. | Hoofd Techniek/Wetenschap/O&O | - | - |
Opleiding van Richard Chesworth
| Imperial College London | Undergraduate Degree |
| University of Oxford | Doctorate Degree |
Statistieken
Internationaal
| Verenigde Staten | 3 |
| Verenigd Koninkrijk | 3 |
Operationeel
| Chief Tech/Sci/R&D Officer | 2 |
| Undergraduate Degree | 1 |
| Doctorate Degree | 1 |
Sectoraal
| Health Technology | 3 |
| Consumer Services | 3 |
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Verwante bedrijven
| Beursgenoteerde bedrijven | 1 |
|---|---|
| KYMERA THERAPEUTICS, INC. | Health Technology |
| Bedrijven in privébezit | 1 |
|---|---|
Epizyme, Inc.
 Epizyme, Inc. BiotechnologyHealth Technology Epizyme, Inc. is a clinical-stage biopharmaceutical company. The firm engages in the discovery, development, and commercialization of novel epigenetic medicines for cancer and other diseases. Its product pipeline is lead by, tazemetostat which targets Non-Hodgkin Lymphoma, molecularly defined solid tumors, non-small-cell lung carcinoma, molecularly targeted tumors, and ovarian cancer. The firm also develops pinometostat for genetically defined acute leukemia, and EZM8266 for sickle cell disease. The company was founded by Robert Horvitz and Zhang Yi on November 1, 2007 and is headquartered in Cambridge, MA. | Health Technology |
- Beurs
- Insiders
- Richard Chesworth
- Ervaring
